Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 17/20 | 1.00 |
| ▸ | SREBF1 | P36956 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | ATM | Q13315 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29458330 | 1.00 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL16535621 | 0.88 | SREBF2 (0.78) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL4282599 | 0.86 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL4282592 | 0.85 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL4279590 | 0.84 | SREBF2 (0.72) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL22122181 | 0.83 | SREBF2 (0.75) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL16535363 | 0.83 | SREBF2 (0.71) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL19733085 | 0.83 | SREBF2 (0.84) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL4282744 | 0.83 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL4288445 | 0.82 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | UESUGI MOTONARI (JP) | 2018-03-15 | — | — | US | claimed |
| EP-2120580-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2017-12-27 | — | — | EP | claimed |
| US-9713613-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE | 2017-07-25 | — | — | US | claimed |
| US-20160193231-A1 | RETT SYNDROME AND TREATMENTS THEREFORE | RETT SYNDROME RES TRUST (US) | 2016-07-07 | — | — | US | claimed |
| US-20160136164-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-19 | — | — | US | claimed |
| EP-3013371-A1 | RETT SYNDROME AND TREATMENTS THEREFORE | Rett Syndrome Research Trust (US) | 2016-05-04 | — | — | EP | claimed |
| US-9187485-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-11-17 | — | — | US | claimed |
| US-20150307501-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-10-29 | — | — | US | claimed |
| US-8927578-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-01-06 | — | — | US | claimed |
| WO-2014210389-A1 | RETT SYNDROME AND TREATMENTS THEREFORE | RETT SYNDROME RESEARCH TRUST (US) | 2014-12-31 | — | — | WO | claimed |
| US-8778976-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2014-07-15 | — | — | US | claimed |
| US-20140045854-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-02-13 | — | — | US | claimed |
| US-20140038984-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-02-06 | — | — | US | claimed |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-10 | — | — | US | claimed |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-03 | — | — | US | claimed |
| US-8207196-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-26 | — | — | US | claimed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | claimed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | claimed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | claimed |
| WO-2020132700-A1 | METHODS OF USING INHIBITORS OF SREBP IN COMBINATION WITH NICLOSAMIDE AND ANALOGS THEREOF | Fgh Biotech Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2018-10-11 | — | — | US | disclosed |
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | UESUGI MOTONARI (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | UESUGI MOTONARI (JP) | 2018-03-15 | — | — | US | disclosed |
| US-9873689-B2 | Synthesis of fatostatin based polycyclic compounds | FGH BIOTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873689-B2 | Synthesis of fatostatin based polycyclic compounds | FGH BIOTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873689-B2 | Synthesis of fatostatin based polycyclic compounds | FGH BIOTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-2120580-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9713613-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE | 2017-07-25 | — | — | US | disclosed |
| US-9713613-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE | 2017-07-25 | — | — | US | disclosed |
| US-20160257675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160221999-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160193231-A1 | RETT SYNDROME AND TREATMENTS THEREFORE | RETT SYNDROME RES TRUST (US) | 2016-07-07 | — | — | US | disclosed |
| EP-3039022-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND BODY WEIGHT RELATED DISORDERS | Baylor College Of Medicine (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160136164-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160136164-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160130264-A1 | Synthesis of Fatostatin Based Polycyclic Compounds | SOUTHWEST RESEARCH INSTITUTE | 2016-05-12 | — | — | US | disclosed |
| US-20160130264-A1 | Synthesis of Fatostatin Based Polycyclic Compounds | SOUTHWEST RESEARCH INSTITUTE | 2016-05-12 | — | — | US | disclosed |
| US-20160130264-A1 | Synthesis of Fatostatin Based Polycyclic Compounds | SOUTHWEST RESEARCH INSTITUTE | 2016-05-12 | — | — | US | disclosed |
| WO-2016073826-A1 | SYNTHESIS OF FATOSTATIN BASED POLYCYCLIC COMPOUNDS | FGH BIOTECH, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073826-A1 | SYNTHESIS OF FATOSTATIN BASED POLYCYCLIC COMPOUNDS | FGH BIOTECH, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20160128985-A1 | Methods and Compositions for the Treatment of Body Weight Related Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160128985-A1 | Methods and Compositions for the Treatment of Body Weight Related Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-12 | — | — | US | disclosed |
| EP-3013371-A1 | RETT SYNDROME AND TREATMENTS THEREFORE | Rett Syndrome Research Trust (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9233941-B2 | Methods and compositions for the treatment of body weight related disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-01-12 | — | — | US | disclosed |
| US-9233941-B2 | Methods and compositions for the treatment of body weight related disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-01-12 | — | — | US | disclosed |
| US-9212179-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-12-15 | — | — | US | disclosed |
| US-9187485-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187485-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187485-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150307501-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307501-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-10-29 | — | — | US | disclosed |
| US-9085566-B2 | Compositions and methods for the treatment of metabolic and related disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085566-B2 | Compositions and methods for the treatment of metabolic and related disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-07-21 | — | — | US | disclosed |
| WO-2015031710-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND BODY WEIGHT RELATED DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2015-03-05 | — | — | WO | disclosed |
| WO-2015031710-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND BODY WEIGHT RELATED DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2015-03-05 | — | — | WO | disclosed |
| US-8927578-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927578-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2014210389-A1 | RETT SYNDROME AND TREATMENTS THEREFORE | RETT SYNDROME RESEARCH TRUST (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140364460-A1 | USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140303213-A1 | Compositions and Methods for the Treatment of Metabolic Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-10-09 | — | — | US | disclosed |
| US-20140235646-A1 | Methods and Compositions for the Treatment of Body Weight Related Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-08-21 | — | — | US | disclosed |
| US-20140235646-A1 | Methods and Compositions for the Treatment of Body Weight Related Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-08-21 | — | — | US | disclosed |
| US-8778976-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778976-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140045854-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-02-13 | — | — | US | disclosed |
| US-20140045854-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-02-13 | — | — | US | disclosed |
| US-20140038984-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-02-06 | — | — | US | disclosed |
| US-20140038984-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-02-06 | — | — | US | disclosed |
| WO-2013110007-A1 | USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-07-25 | — | — | WO | disclosed |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8207196-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | HCCS, PCNA, MKI67 | SREBF2 1767/4885SREBF1 1737/4885MAPT 4275/4885 |
| US-20160128985-A1 | Methods and Compositions for the Treatment of Body Weight Related Disorders | ABAT, CPT1B, LRBA | SREBF2 872/4885SREBF1 897/4885MAPT 2719/4885 |
| US-20140045854-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | HCCS, PCNA, MKI67 | SREBF2 1767/4885SREBF1 1737/4885MAPT 4275/4885 |
| US-20140235646-A1 | Methods and Compositions for the Treatment of Body Weight Related Disorders | ABAT, CPT1B, LRBA | SREBF2 872/4885SREBF1 897/4885MAPT 2719/4885 |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | FABP4, LIPC, PNLIP | SREBF2 17/4885SREBF1 9/4885MAPT 3356/4885 |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885SREBF1 15/4885MAPT 3510/4885 |
| US-20150307501-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | FABP4, LIPC, PC | SREBF2 37/4885SREBF1 19/4885MAPT 3529/4885 |
| US-20140303213-A1 | Compositions and Methods for the Treatment of Metabolic Disorders | FABP4, LIPC, PNLIP | SREBF2 67/4885SREBF1 41/4885MAPT 4122/4885 |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885SREBF1 15/4885MAPT 3510/4885 |
| US-20160257675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885SREBF1 15/4885MAPT 3510/4885 |
| US-20160130264-A1 | Synthesis of Fatostatin Based Polycyclic Compounds | PTMA, FABP4, PLIN5 | SREBF2 38/4885SREBF1 98/4885MAPT 4347/4885 |
| US-20140038984-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | FABP4, LIPC, PC | SREBF2 37/4885SREBF1 19/4885MAPT 3529/4885 |
| US-20160136164-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | HCCS, PCNA, MKI67 | SREBF2 1779/4885SREBF1 1738/4885MAPT 4269/4885 |
| US-20160221999-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885SREBF1 15/4885MAPT 3510/4885 |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 32/4885SREBF1 16/4885MAPT 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.